pCPA Activity Overview

Status Total Negotiations Summary
Active Negotiations 32 Non-oncology: 20
Oncology: 12
Under Consideration for Negotiation 24 Non-oncology: 19
Oncology: 5
Completed Negotiations 642 With Letter of Intent: 550
Without agreement: 92
Negotiations That Were Not Pursued 98

pCPA Activity in the last four weeks

Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.

Engagement Letters Issued in the last four weeks

Brand Name Manufacturer Indication Engagement Date
Yescarta Gilead Sciences Canada Inc. for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy
Skyrizi AbbVie Corporation For the treatment of adults with moderately to severely active Crohn's disease
Enhertu AstraZeneca Canada Inc. Indicated as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer
Nubeqa Bayer Inc. For the treatment of patients with metastatic castration sensitive prostate cancer (mCSPC) in combination with docetaxel
Oxlumo Alnylam Netherlands B.V. primary hyperoxaluria type 1
Empaveli Sobi Canada Inc. For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor
Mezera AVIR Pharma Inc. Ulcerative Colitis

Negotiations Completed in the last four weeks with a Letter of Intent

Brand Name Manufacturer Indication Engagement Date Close Date
Rinvoq AbbVie Corporation atopic dermatitis
Tezspire AstraZeneca Canada Inc. add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma
Cabometyx Ipsen Biopharmaceuticals For the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that has progressed following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy and who are radioactive iodine-refracto

Negotiations Completed in the last four weeks without Agreement

Brand Name Manufacturer Indication Engagement Date Close Date
No negotiations completed without agreement in the last four weeks

Negotiations that pCPA Decided Not to Pursue in the last four weeks

Brand Name Manufacturer Indication Close Date
No negotiations that pCPA decided not to pursue in the last four weeks